Pfizer’s Karen Bien elected to board of SAFE-BioPharma

Friday, June 29, 2012 09:57 AM

Karen Bien, director of business technology on Pfizer’s acquisition, collaboration and divestiture team, has been elected to the board of directors of SAFE-BioPharma Association, the strategic non-profit collaboration that developed and manages the global SAFE-BioPharma digital identity and digital signature standard for the life science and healthcare sectors.

In the volunteer board position, Bien will participate in leading SAFE-BioPharma’s global expansion involving biopharmaceutical industry partners in governments, research institutions and the U.S. healthcare system.

Bien has extensive leadership experience across the pharmaceutical and healthcare industries. At Pfizer, she leads a team that provides technical services and support required for external alliances. She previously held a variety of compliance, continuous improvement and related roles at Wyeth Pharmaceuticals (now Pfizer), Siemens Medical Systems and Innovex.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs